Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Oncology · Familial Prostate Cancer

Treatment Strategies: PARP Inhibitors and Precision Medicine

At a Glance

For men with advanced familial prostate cancer, precision medicine uses genetic testing to target specific tumor weaknesses. PARP inhibitors effectively treat cancers with BRCA mutations, while theranostics like Pluvicto target PSMA-positive tumors, offering new hope when standard therapies fail.

If you are newly diagnosed, it is crucial to understand that many men with familial prostate cancer are cured entirely with standard localized treatments—like surgery or radiation—and never need the advanced therapies described on this page. However, it is important to know what options exist if the cancer does spread or becomes resistant to standard hormone blockers.

When prostate cancer reaches an advanced stage—specifically metastatic castration-resistant prostate cancer (mCRPC), where the cancer grows despite low testosterone levels—treatment shifts from a “one-size-fits-all” approach to precision medicine. This means your treatment is chosen based on the specific genetic “weak spots” found in your cancer cells [1][2].

Targeted Therapy: PARP Inhibitors

For men whose cancer has defects in the “repair crew” genes (like BRCA1, BRCA2, or ATM), a class of drugs called PARP inhibitors has become a standard of care.

  • How They Work: PARP is an enzyme that helps cells fix minor DNA damage. In a healthy cell, if PARP is blocked, the cell uses a backup system (like BRCA2) to finish the repair. However, if your cancer already has a broken BRCA2 gene, blocking PARP leaves the cancer cell with no way to fix itself, causing it to die. This is called “synthetic lethality” [3][4].
  • The Drugs: Common PARP inhibitors include olaparib, talazoparib, and rucaparib [5][6].
  • Side Effects: While highly effective, these drugs can cause side effects like significant fatigue and anemia (low red blood cell count), which your care team will need to monitor closely [3].
  • Combination Power: Doctors often combine PARP inhibitors with hormone therapies (like abiraterone or enzalutamide). These combinations have been shown to delay disease progression more effectively than hormone therapy alone, especially in men with BRCA mutations [7][8][9].

Precision Imaging: Theranostics (Pluvicto)

A groundbreaking approach called theranostics (a blend of “therapy” and “diagnostics”) targets a protein called PSMA (Prostate-Specific Membrane Antigen) that is found on the surface of most prostate cancer cells [10].

  • 177Lu-PSMA-617 (Pluvicto): This is a “search-and-destroy” molecule. It consists of a targeting part that finds PSMA and a radioactive payload (Lutetium-177). Once it hitches onto a cancer cell, it releases radiation that kills the cell and its immediate neighbors [11][12].
  • The VISION Trial: This major study showed that Pluvicto significantly improved survival for men with PSMA-positive mCRPC who had already tried other standard treatments [13][14].

Why Double Sequencing is Critical

To access these treatments, your doctors must perform two different types of genetic testing. This is often called “double sequencing.”

  1. Germline Sequencing: Tests the DNA you were born with (usually via blood or saliva). This tells you if the cancer is hereditary and provides information for your family members [15].
  2. Somatic Sequencing: Tests the DNA inside the tumor (using a biopsy or a “liquid biopsy” of your blood). Over time, cancer can develop new mutations that you weren’t born with. Somatic testing captures these changes and may reveal new “targets” for drugs like PARP inhibitors that germline testing would miss [16][17].

By mapping both your inherited risk and the tumor’s specific mutations, your medical team can build a treatment sequence designed specifically for your cancer’s biology [17][1].

Common questions in this guide

What are PARP inhibitors for prostate cancer?
PARP inhibitors are targeted drugs used for men whose prostate cancer has DNA repair gene mutations, such as BRCA1 or BRCA2. They work by blocking an enzyme cancer cells use to fix their DNA, which leaves the damaged cancer cells unable to survive and causes them to die.
Why is double sequencing important for my treatment?
Double sequencing involves performing both germline and somatic genetic testing. Germline testing looks at the DNA you were born with, while somatic testing looks at the DNA inside your tumor. Together, they help doctors find specific genetic weaknesses in your cancer to target with precision medicine.
Am I a candidate for Pluvicto (177Lu-PSMA-617)?
Pluvicto is a targeted radiation therapy used for advanced prostate cancer that has spread and stopped responding to other treatments. Your doctor will use a specific PET scan to see if your cancer cells have a protein called PSMA on their surface, which is required for this treatment to work.
What are the side effects of PARP inhibitors?
While highly effective, PARP inhibitors can cause significant side effects like extreme fatigue and anemia, which is a low red blood cell count. Your care team will monitor your blood levels closely with regular lab tests while you take these medications.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my genetic testing, do I have a BRCA1, BRCA2, or ATM mutation, and how does that specific gene affect my potential response to PARP inhibitors?
  2. 2.Am I a candidate for a combination therapy, like olaparib plus abiraterone, or should we start with a single agent?
  3. 3.Has my cancer been tested for PSMA expression through a PET scan to see if I am eligible for 177Lu-PSMA-617 (Pluvicto)?
  4. 4.Should we perform a 'liquid biopsy' (ctDNA) to see if my cancer's genetic profile has changed since my original diagnosis?
  5. 5.How will we monitor and manage potential side effects like anemia or fatigue while I am on a PARP inhibitor?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    French AFU Cancer Committee Guidelines - Update 2024-2026: Prostate cancer - Management of metastatic disease and castration resistance.

    Ploussard G, Dariane C, Mathieu R, et al.

    The French journal of urology 2024; (34(12)):102710 doi:10.1016/j.fjurol.2024.102710.

    PMID: 39581665
  2. 2

    Advances in Targeted Therapy for Metastatic Prostate Cancer.

    Grewal K, Dorff TB, Mukhida SS, et al.

    Current treatment options in oncology 2025; (26(6)):465-475 doi:10.1007/s11864-025-01323-7.

    PMID: 40299225
  3. 3

    Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial.

    Smith MR, Scher HI, Sandhu S, et al.

    The Lancet. Oncology 2022; (23(3)):362-373 doi:10.1016/S1470-2045(21)00757-9.

    PMID: 35131040
  4. 4

    Rucaparib or Physician's Choice in Metastatic Prostate Cancer.

    Fizazi K, Piulats JM, Reaume MN, et al.

    The New England journal of medicine 2023; (388(8)):719-732 doi:10.1056/NEJMoa2214676.

    PMID: 36795891
  5. 5

    Olaparib for Metastatic Castration-Resistant Prostate Cancer.

    de Bono J, Mateo J, Fizazi K, et al.

    The New England journal of medicine 2020; (382(22)):2091-2102 doi:10.1056/NEJMoa1911440.

    PMID: 32343890
  6. 6

    First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial.

    Matsubara N, Azad AA, Agarwal N, et al.

    The Lancet. Oncology 2025; (26(4)):470-480 doi:10.1016/S1470-2045(25)00030-0.

    PMID: 40179906
  7. 7

    Tolerability of Olaparib Combined with Abiraterone in Patients with Metastatic Castration-resistant Prostate Cancer: Further Results from the Phase 3 PROpel Trial.

    Saad F, Armstrong AJ, Oya M, et al.

    European urology oncology 2024; (7(6)):1394-1402 doi:10.1016/j.euo.2024.03.006.

    PMID: 38582650
  8. 8

    FDA Approval Summary: Olaparib in Combination With Abiraterone for Treatment of Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer.

    Fallah J, Xu J, Weinstock C, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2024; (42(5)):605-613 doi:10.1200/JCO.23.01868.

    PMID: 38127780
  9. 9

    Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial.

    Fizazi K, Azad AA, Matsubara N, et al.

    Lancet (London, England) 2025; (406(10502)):461-474 doi:10.1016/S0140-6736(25)00683-X.

    PMID: 40683287
  10. 10

    TheraP: a randomized phase 2 trial of 177 Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603).

    Hofman MS, Emmett L, Violet J, et al.

    BJU international 2019; (124 Suppl 1()):5-13 doi:10.1111/bju.14876.

    PMID: 31638341
  11. 11

    Neoadjuvant lutetium PSMA, the TIME and immune response in high-risk localized prostate cancer.

    Eapen RS, Williams SG, Macdonald S, et al.

    Nature reviews. Urology 2024; (21(11)):676-686 doi:10.1038/s41585-024-00913-8.

    PMID: 39112733
  12. 12

    PSMA-617 inhibits proliferation and potentiates the 177Lu-PSMA-617-induced death of human prostate cancer cells.

    Zhao Y, Culman J, Cascorbi I, et al.

    Naunyn-Schmiedeberg's archives of pharmacology 2023; (396(11)):3315-3326 doi:10.1007/s00210-023-02539-w.

    PMID: 37284895
  13. 13

    Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.

    Sartor O, de Bono J, Chi KN, et al.

    The New England journal of medicine 2021; (385(12)):1091-1103 doi:10.1056/NEJMoa2107322.

    PMID: 34161051
  14. 14

    PSMA-Targeted Radiopharmaceuticals in Prostate Cancer: Current Data and New Trials.

    Ramnaraign B, Sartor O

    The oncologist 2023; (28(5)):392-401 doi:10.1093/oncolo/oyac279.

    PMID: 36806966
  15. 15

    Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now.

    Shore N, Nielsen SM, Esplin ED, et al.

    JCO oncology practice 2025; (21(6)):747-753 doi:10.1200/OP-24-00626.

    PMID: 39700441
  16. 16

    Aggressive prostate cancer with somatic loss of the homologous recombination repair gene FANCA: a case report.

    Hongo H, Kosaka T, Aimono E, et al.

    Diagnostic pathology 2020; (15(1)):5 doi:10.1186/s13000-019-0916-z.

    PMID: 31931827
  17. 17

    Genomic profiling and clinical utility of circulating tumor DNA in metastatic prostate cancer: SCRUM-Japan MONSTAR SCREEN project.

    Shiota M, Matsubara N, Kato T, et al.

    BJC reports 2024; (2(1)):28 doi:10.1038/s44276-024-00049-7.

    PMID: 39516321

This page explains precision medicine and targeted therapies for educational purposes only. It does not replace professional medical advice. Always discuss genetic testing and treatment options with your oncologist.

Get notified when new evidence is published on Familial prostate carcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.